Endosomal Toll-like receptors in clinically overt and silent autoimmunity

Immunological Reviews

Volumn 269, Issue 1, 2016, Pages 76-84

  Clancy, Robert M ^a   Markham, Androo J ^a   Buyon, Jill P ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti SSA Ro60; Autoimmunity; Lupus; Neonatal lupus; TLR7

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; DOUBLE STRANDED RNA; HLA DRB3 ANTIGEN; HYDROXYCHLOROQUINE; INTERFERON; INTERFERON REGULATORY FACTOR 5; NUCLEIC ACID; RNA; RO ANTIBODY; SINGLE STRANDED RNA; STAT4 PROTEIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; UNTRANSLATED RNA; RIBONUCLEOPROTEIN; SS-A ANTIGEN;

ANTIGEN RECOGNITION; APOPTOSIS; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE COURSE; ENDOSOME; FETUS DEVELOPMENT; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HEART BLOCK; HUMAN; IMMUNOPHENOTYPING; LUPUS VULGARIS; NEWBORN DISEASE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RASH; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE INJURY; VIRUS INFECTION; ANIMAL; ASYMPTOMATIC DISEASE; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM; NEWBORN; PASSIVE IMMUNIZATION;

ANIMALS; ASYMPTOMATIC DISEASES; AUTOANTIBODIES; AUTOIMMUNITY; ENDOSOMES; HEART BLOCK; HUMANS; HYDROXYCHLOROQUINE; IMMUNITY, MATERNALLY-ACQUIRED; INFANT, NEWBORN; LUPUS ERYTHEMATOSUS, SYSTEMIC; RIBONUCLEOPROTEINS; TOLL-LIKE RECEPTOR 7;

EID: 84950109341     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12383     Document Type: Article

References (59)

1. Horton CG, Pan ZJ, Farris AD. Targeting Toll-like receptors for treatment of SLE. Mediators Inflamm 2010;2010:11-20.
2. Schnare M, Rollinghoff M, Qureshi S. Toll-like receptors: sentinels of host defence against bacterial infection. Int Arch Allergy Immunol 2006;139:75-85.
3. Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochem Biophys Res Commun 2009;388:621-625.
4. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005;17:1-14.
5. Lafyatis R, York M, Marshak-Rothstein A. Antimalarial agents: closing the gate on Toll-like receptors? Arthritis Rheum 2006;54:3068-3070.
6. Lovgren T, Eloranta ML, Bave U, Alm GV, Ronnblom L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 2004;50:1861-1872.
7. Clancy RM, Alvarez D, Komissarova E, Barrat FJ, Swartz J, Buyon JP. Ro60-associated single-stranded RNA links inflammation with fetal cardiac fibrosis via ligation of TLRs: a novel pathway to autoimmune-associated heart block. J Immunol 2010;184:2148-2155.
8. Rivera TL, et al. Disease progression in mothers of children enrolled in the Research Registry for Neonatal Lupus. Ann Rheum Dis 2009;68:828-835.
9. Arbuckle MR, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526-1533.
10. Mills RE, et al. Unbiased modifier screen reveals that signal strength determines the regulatory role murine TLR9 plays in autoantibody production. J Immunol 2015;194:3675-3686.
11. Barton GM, Kagan JC. A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat Rev Immunol 2009;9:535-542.
12. Fukui R, et al. Unc93B1 biases Toll-like receptor responses to nucleic acid in dendritic cells toward DNA- but against RNA-sensing. J Exp Med 2009;206:1339-1350.
13. Fukui R, et al. Unc93B1 restricts systemic lethal inflammation by orchestrating Toll-like receptor 7 and 9 trafficking. Immunity 2011;35:69-81.
14. Nickerson KM, et al. TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus. J Immunol 2010;184:1840-1848.
15. Nundel K, et al. Cell-intrinsic expression of TLR9 in autoreactive B cells constrains BCR/TLR7-dependent responses. J Immunol 2015;194:2504-2512.
16. Deane JA, et al. Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity 2007;27:801-810.
17. Lee PY, et al. TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus. J Exp Med 2008;205:2995-3006.
18. Bave U, Magnusson M, Eloranta ML, Perers A, Alm GV, Ronnblom L. Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J Immunol 2003;171:3296-3302.
19. Guiducci C, et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 2010;465:937-941.
20. Stohl W, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012;64:2328-2337.
21. St Clair EW, et al. Rituximab therapy for primary Sjogren's syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum 2013;65:1097-1106.
22. Hung T, et al. The Ro60 autoantigen binds endogenous retroelements and regulates inflammatory gene expression. Science 2015;350:455-459.
23. Xue D, et al. A lupus-like syndrome develops in mice lacking the Ro 60-kDa protein, a major lupus autoantigen. Proc Natl Acad Sci USA 2003;100:7503-7508.
24. Clark K, Plater L, Peggie M, Cohen P. Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation. J Biol Chem 2009;284:14136-14146.
25. McGaha TL, Chen Y, Ravishankar B, van Rooijen N, Karlsson MC. Marginal zone macrophages suppress innate and adaptive immunity to apoptotic cells in the spleen. Blood 2011;117:5403-5412.
26. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994;179:1317-1330.
27. Miranda ME, et al. Accessibility of SSA/Ro and SSB/La antigens to maternal autoantibodies in apoptotic human fetal cardiac myocytes. J Immunol 1998;161:5061-5069.
28. Reed JH, Clancy RM, Purcell AW, Kim MY, Gordon TP, Buyon JP. beta2-glycoprotein I and protection from anti-SSA/Ro60-associated cardiac manifestations of neonatal lupus. J Immunol 2011;187:520-526.
29. Reed JH, et al. Different temporal expression of immunodominant Ro60/60 kDa-SSA and La/SSB apotopes. Clin Exp Immunol 2007;148:153-160.
30. Reed JH, Sim S, Wolin SL, Clancy RM, Buyon JP. Ro60 requires Y3 RNA for cell surface exposure and inflammation associated with cardiac manifestations of neonatal lupus. J Immunol 2013;191:110-116.
31. Clancy RM, et al. Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and -SSB/La antibodies in the pathogenesis of congenital heart block. J Clin Invest 2006;116:2413-2422.
32. Clancy RM, et al. Transdifferentiation of cardiac fibroblasts, a fetal factor in anti-SSA/Ro-SSB/La antibody-mediated congenital heart block. J Immunol 2002;169:2156-2163.
33. Dieude M, et al. Association of autoantibodies to nuclear lamin B1 with thromboprotection in systemic lupus erythematosus: lack of evidence for a direct role of lamin B1 in apoptotic blebs. Arthritis Rheum 2002;46:2695-2707.
34. O'Brien CA, Wolin SL. A possible role for the 60-kD Ro autoantigen in a discard pathway for defective 5S rRNA precursors. Genes Dev 1994;8:2891-2903.
35. Chen X, Smith JD, Shi H, Yang DD, Flavell RA, Wolin SL. The Ro autoantigen binds misfolded U2 small nuclear RNAs and assists mammalian cell survival after UV irradiation. Curr Biol 2003;13:2206-2211.
36. Shi H, O'Brien CA, Van Horn DJ, Wolin SL. A misfolded form of 5S rRNA is complexed with the Ro and La autoantigens. RNA 1996;2:769-784.
37. Sim S, Weinberg DE, Fuchs G, Choi K, Chung J, Wolin SL. The subcellular distribution of an RNA quality control protein, the Ro autoantigen, is regulated by noncoding Y RNA binding. Mol Biol Cell 2009;20:1555-1564.
38. Leach JL, Sedmak DD, Osborne JM, Rahill B, Lairmore MD, Anderson CL. Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport. J Immunol 1996;157:3317-3322.
39. Buyon JP, Friedman DM. Neonatal lupus. In: Lahita RG, Tsokos G, Buyon JP, Koike T eds. Systemic Lupus Erythematosus. 5th edn. San Diego: Academic Press, 2011:541-567.
40. Izmirly PM, et al. Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation 2011;124:1927-1935.
41. Waltuck J, Buyon JP. Autoantibody-associated congenital heart block: outcome in mothers and children. Ann Intern Med 1994;120:544-551.
42. Clancy RM, Markham AJ, Reed JH, Blumenberg M, Halushka MK, Buyon JP. Targeting downstream transcription factors and epigenetic modifications following Toll-like receptor 7/8 ligation to forestall tissue injury in anti-Ro60 associated heart block. J Autoimmun 2015;1:4-8.
43. Costedoat-Chalumeau N, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:3284-3290.
44. Kelly KM, et al. "Endogenous adjuvant" activity of the RNA components of lupus autoantigens Sm/RNP and Ro 60. Arthritis Rheum 2006;54:1557-1567.
45. Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 2011;186:4794-4804.
46. Lamphier M, et al. Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo. Mol Pharmacol 2014;85:429-440.
47. Niewold TB, Rivera TL, Buyon JP, Crow MK. Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupus. Arthritis Rheum 2008;58:541-546.
48. Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK. High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 2007;8:492-502.
49. Izmirly PM, et al. Elevated regulatory mediators and interferon gamma associated responses, but not interferon alpha, BLyS or IP-10, accompany high-titer anti-Ro autoantibodies in asymptomatic mothers of children with neonatal lupus. Arthritis Rheum 2014;9S:1605 (Abstract).
50. Frohlich A, et al. IL-21 receptor signaling is integral to the development of Th2 effector responses in vivo. Blood 2007;109:2023-2031.
51. Ray JP, Marshall HD, Laidlaw BJ, Staron MM, Kaech SM, Craft J. Transcription factor STAT3 and type I interferons are corepressive insulators for differentiation of follicular helper and T helper 1 cells. Immunity 2014;40:367-377.
52. Dillon SR, et al. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis Res Ther 2010;12:R48.
53. Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 2002;13:323-340.
54. Subramanian S, et al. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci USA 2006;103:9970-9975.
55. Izmirly PM, et al. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis 2010;69:1827-1830.
56. Izmirly PM, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 2012;126:76-82.
57. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006;25:417-428.
58. Chung SA, et al. Differential genetic associations for systemic lupus erythematosus based on anti-dsDNA autoantibody production. PLoS Genet 2011;7:e1001323.
59. Poole BD, Templeton AK, Guthridge JM, Brown EJ, Harley JB, James JA. Aberrant Epstein-Barr viral infection in systemic lupus erythematosus. Autoimmun Rev 2009;8:337-342.